Posted by Michael Wonder on 18 Jun 2025
Duke Street Bio receives FDA fast track designation for DSB2455
10 June 2025 - Duke Street Bio today announced that the US FDA has granted fast track designation to DSB2455, its next generation, CNS active selective PARP1 inhibitor, for the treatment of patients with brain metastases originating from primary triple negative breast cancer tumours harbouring BRCA1/2 and/or homologous recombination repair alterations.
